Cargando…
Novel monoclonal antibodies against thymidine kinase 1 and their potential use for the immunotargeting of lung, breast and colon cancer cells
BACKGROUND: Thymidine kinase 1 (TK1) is a pyrimidine salvage pathway enzyme that is up-regulated in malignant tissues and elevated in the serum of cancer patients. While TK1 has been well established as a tumor biomarker, little has been done to explore its potential as a tumor target. Recently, we...
Autores principales: | Velazquez, Edwin J., Brindley, Taylor D., Shrestha, Gajendra, Bitter, Eliza E., Cress, Jordan D., Townsend, Michelle H., Berges, Bradford K., Robison, Richard A., Weber, K. Scott, O’Neill, Kim L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160906/ https://www.ncbi.nlm.nih.gov/pubmed/32317865 http://dx.doi.org/10.1186/s12935-020-01198-8 |
Ejemplares similares
-
Membrane expression of thymidine kinase 1 and potential clinical relevance in lung, breast, and colorectal malignancies
por: Weagel, Evita G., et al.
Publicado: (2018) -
Thymidine kinase 1 through the ages: a comprehensive review
por: Bitter, Eliza E., et al.
Publicado: (2020) -
Selection of human single domain antibodies (sdAb) against thymidine kinase 1 and their incorporation into sdAb-Fc antibody constructs for potential use in cancer therapy
por: Velazquez, Edwin J., et al.
Publicado: (2022) -
Immunotargeting of cancer stem cells
por: Kwiatkowska-Borowczyk, Eliza P., et al.
Publicado: (2015) -
Immunotargeting in the management of psoriasis
por: Kaffenberger, Benjamin H, et al.
Publicado: (2013)